SAB BIO Secures $175 Million Funding to Advance Type 1 Diabetes Immunotherapy Through Phase 2b Trial
Key Insights
SAB BIO (search) raised $175 million in an oversubscribed private placement with participation from strategic investor Sanofi and multiple institutional investors to fund its type 1 diabetes (search) program.
The proceeds will fully fund the pivotal Phase 2b SAFEGUARD study evaluating SAB-142, a human anti-thymocyte immunoglobulin (search) therapy for delaying progression of autoimmune T1D (search) in newly diagnosed patients.
The financing extends the company's cash runway into mid-2028, with potential for up to $284 million in additional proceeds if milestone-based warrants are exercised.
SAB BIO (search) has successfully completed a $175 million oversubscribed private placement financing that will fully fund its pivotal Phase 2b clinical trial for SAB-142, an investigational immunotherapy targeting autoimmune type 1 diabetes (search) (T1D). The Miami-based clinical-stage biopharmaceutical company announced the financing on July 21, 2025, with participation from strategic investor Sanofi alongside multiple new and existing institutional investors.
Strategic Investment and Investor Participation
The private placement attracted significant interest from both new and existing investors, demonstrating confidence in SAB BIO (search)'s novel immunotherapy platform. Strategic investor Sanofi joined the financing alongside new investors including RA Capital Management (search), Commodore Capital (search), Vivo Capital (search), Blackstone Multi-Asset Investing (search), Spruce Street Capital, Forge Life Science Partners, and Woodline Partners LP. Existing investors Sessa Capital, the T1D Fund, and ATW Partners also participated in the oversubscribed round.
Under the terms of the securities purchase agreement, SAB BIO (search) will issue up to 1,000,000 shares of Series B nonvoting convertible preferred stock, convertible into up to 100,000,000 shares of common stock at a conversion price of $1.75 per share. The company will also issue warrants to purchase up to 1,500,000 shares of Series B preferred stock, potentially generating up to an additional $284 million in gross proceeds if exercised in full.
Funding the SAFEGUARD Study
The net proceeds from the private placement are specifically earmarked to fully fund the Phase 2b SAFEGUARD study of SAB-142 in Stage 3 autoimmune T1D (search) patients, along with working capital and general corporate purposes. The SAFEGUARD study represents a pivotal trial evaluating SAB-142's ability to delay progression of autoimmune T1D in newly diagnosed patients.
Combined with the company's current cash and cash equivalents, the financing proceeds are expected to extend SAB BIO (search)'s cash runway into the middle of 2028, providing substantial runway to complete the critical Phase 2b trial and advance the program toward potential regulatory milestones.
Novel Immunotherapy Platform
SAB-142 is a human anti-thymocyte immunoglobulin (search) (hIgG) developed using SAB BIO (search)'s proprietary immunotherapy platform. The therapy targets autoimmune T1D (search) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression.
The company's drug development production system utilizes advanced genetic engineering and antibody science to develop Transchromosomic (Tc) Bovine™, described as the only transgenic animal with a human artificial chromosome. This platform enables SAB BIO (search) to generate a diverse repertoire of specifically targeted, high-potency, human IgGs without requiring convalescent plasma or human donors.
Market Positioning and Clinical Development
SAB BIO (search) positions itself as a clinical-stage biopharmaceutical company focused on developing human, multi-specific, high-potency immunoglobulins to treat and prevent immune and autoimmune disorders. The company's lead asset, SAB-142, specifically targets the significant unmet medical need in autoimmune T1D (search) treatment.
The private placement is expected to close on or about July 22, 2025, subject to customary closing conditions. Leerink Partners served as lead placement agent for the financing, with UBS Investment Bank, Chardan, and Oppenheimer & Co. acting as joint placement agents.